Corcept Therapeutics (NASDAQ:CORT) had its price target reduced by equities researchers at B. Riley from $30.00 to $22.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price objective suggests a potential upside of 76.42% from the stock’s previous close.
Several other research firms also recently weighed in on CORT. Stifel Nicolaus downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target for the company. in a research report on Thursday, May 31st. BidaskClub raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 19th. ValuEngine raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Finally, Zacks Investment Research raised Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Friday, April 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $22.80.
Best Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Dan Caplinger]
Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here's why they did so well.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
Best Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Joseph Griffin]
Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.86 million shares from the previous 3.45 million. The stock recently traded at $287.00, within a 52-week range of $244.28 to $370.57.
- [By Brian Feroldi]
Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.
- [By George Budwell]
Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout?
Best Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Max Byerly]
Gables Capital Management Inc. purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,023 shares of the medical research company’s stock, valued at approximately $174,000.
- [By ]
Amgen's (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen's share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen -- at least for the next few years.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.62 million shares from the previous level of 9.79 million. Shares were last seen at $178.26, in a 52-week trading range of $153.56 to $201.23.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Amgen (AMGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Best Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
- [By Stephan Byrd]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Keith Speights]
Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.
No comments:
Post a Comment